- Adolor presented at the William Blair conference on 9/7/2011 - see full webcast and notes calendar here.
- ADLR research page has more details on clinical programs, etc.
- See below for my webcast notes:
- Presenters: CEO and VP, Medical Affairs/ Medical Director
- no slide deck
- at least half (conservatively) of chronic opioid users have OIC, even with laxative use in some form
- Phase 2 trials had 2 week screening period and 1 week to establish baseline SBMs. Then 4 week treatment period. Then everyone gets placebo "washout" for one week
- Our definition of responder had to meet the criteria 3 of 4 weeks. Saw response in 56% of paients on 0.25 mg BID vs 26% placebo, 43% for 0.25 mg QD vs 29% placebo
- "Number needed to treat" NNT calculated as 3 patients for one to benefit. "very low and highly clinically relevant"
- We now have about 45 salespeople in the field. We have 100% effort from these instead of some effort from larger GSK hosptial force...a "tradeoff". There is more white space now where we don't have people, focus more on nonpersonal promotionin those areas.
- Phase 3 - larger study, similar endpoints, will do long-term safety study. We'll be ready to initiate early next year
- Once daily dosing in this space- tend to see more and more severe GI AE's historically...maybe need sustained release formulations [Comments when asked about potential of pursuing once daily 0.25mg dose for competitive advantage....these patients take multipel drugs multiple times a day so QD vs BID isn't a big factor it seems]